OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 12, 2024-- Takeda ( TSE:4502/NYSE:TAK ) will host an investor R&D Day today beginning at 8:30 a.m. JST in Tokyo. The meeting will focus on programs in the company’s late-stage pipeline, the transformative value they could deliver to patients, and the market opportunities they represent. “We are focused on advancing our innovative pipeline and accelerating late-stage programs to deliver sustainable revenue growth to 2030 and beyond, building upon the strong momentum of our Growth and Launch Products,” said Christophe Weber, Takeda chief executive officer. “The first three Phase 3 programs will read out in 2025, initiating a cadence of potential filings across multiple indications over the next several years.” Eight Regulatory Filings in FY2025 – FY2029 The late-stage pipeline includes oveporexton (TAK-861), zasocitinib (TAK-279), rusfertide (TAK-121), mezagitamab (TAK-079), fazirsiran (TAK-999) and elritercept (TAK-226). Combined these programs have potential peak revenue 1 of $10B - $20B. Data from three Phase 3 programs is expected to read out in 2025: Filings for these three indications are expected in fiscal years 2025 and 2026. Five additional indication filings for late-stage programs are on pace for fiscal years 2027 through 2029: “Takeda has established an exciting, late-stage pipeline of transformative therapies that we believe will deliver value to our company and, most importantly, to the patients we serve around the world,” said Andy Plump, president of R&D at Takeda. “As we continue scaling our capabilities and maximizing R&D investment to deliver the late-stage pipeline, we are also progressing an exciting early-stage pipeline, supporting a cutting-edge research organization, and focusing on creative business development across our therapeutic areas to sustain Takeda’s future and continue to meet significant unmet patient needs.” 2024 R&D Day Agenda The meeting includes the following presentations and speakers: A Global, Innovation-Driven Biopharmaceutical Company Christophe Weber, President & CEO R&D Strategy and Pipeline Highlights Andy Plump, President, Research and Development Neuroscience: Deep-Dive on Orexin Franchise Sarah Sheikh, Head of Neuroscience Therapeutic Area Unit and Head of Global Development Ramona Sequeira, President of Global Portfolio Division Gastrointestinal and Inflammation: Deep-Dive on Zasocitinib, Rusfertide, Mezagitamab, Fazirsiran Chinwe Ukomadu, Head of Gastrointestinal and Inflammation Therapeutic Area Unit Ramona Sequeira, President of Global Portfolio Division Oncology: Deep-Dive on Elritercept – Newly Announced Business Development Deal Teresa Bitetti, President Global Oncology Business Unit P.K. Morrow, Head of Oncology Therapeutic Area Unit Webcast Details A live webcast of the meeting begins at 8:30 a.m. JST December 13 (6:30 p.m. EST December 12). Presentations are available on the Investor Relations section of Takeda’s website where a video replay will be available following the meeting. About Takeda Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com . Important Notice For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov . Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results. Peak Sales and PTRS Estimates References in this press release to peak revenue potential ranges are estimates that have not been adjusted for probability of technical and regulatory success (PTRS) and should not be considered a forecast or target. These peak revenue potential ranges represent Takeda’s assessments of various possible future commercial scenarios that may or may not occur. References in this press release to PTRS are to internal estimates of Takeda regarding the likelihood of obtaining regulatory approval for a particular product in a particular indication. These estimates reflect the subjective judgment of responsible Takeda personnel and have been approved by Takeda’s Portfolio Review Committee for use in internal planning. Medical Information This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. Elritercept license agreement Elritercept is included for reference only. Takeda entered into an exclusive license agreement with Keros for global rights, in all territories outside of mainland China, Hong Kong and Macau, to Elritercept. The closing of the transaction is subject to receipt of regulatory approval(s), expected in the first calendar quarter of 2025. Takeda does not currently have rights to Elritercept. ___________________________ 1 References in this presentation to peak revenue potential are estimates that have not been adjusted for probability of technical and regulatory success (PTRS) and should not be considered a forecast or target. These peak revenue ranges represent Takeda’s assessments of various possible future commercial scenarios that may or may not occur. View source version on businesswire.com : https://www.businesswire.com/news/home/20241211148492/en/ CONTACT: Investor Relations Christopher O’Reilly Christopher.oreilly@takeda.com +81 (0) 90-6481-3412 Takeda Media Relations media_relations@takeda.com KEYWORD: MASSACHUSETTS UNITED STATES JAPAN NORTH AMERICA ASIA PACIFIC INDUSTRY KEYWORD: ONCOLOGY HEALTH NEUROLOGY CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Takeda Pharmaceutical Company Limited Copyright Business Wire 2024. PUB: 12/12/2024 05:30 PM/DISC: 12/12/2024 05:30 PM http://www.businesswire.com/news/home/20241211148492/en
San Francisco 49ers running back Christian McCaffrey and top backup Jordan Mason are being placed on injured reserve. McCaffrey left the snowy field in Buffalo on Sunday night after a 5-yard gain that was preceded by him heading to the sideline in apparent pain at the end of an 18-yard run. McCaffrey was diagnosed with a posterior cruciate ligament injury in his right knee and did not play in the second half. The 49ers also lost Jordan Mason, who emerged in a starting role with McCaffrey out the first two months of the season, to an ankle injury. Head coach Kyle Shanahan said Monday that Mason has a high-ankle sprain, which typically requires a recovery window of 4-6 weeks. Those moves push rookie Isaac Guerendo into the RB1 spot. He scored the team's only touchdown at Buffalo. The IR slots in San Francisco are manned by multiple starters, including wide receiver Brandon Aiyuk, linebacker Dre Greenlaw, defensive tackle Javon Hargrave and safety Talanoa Hufanga. Mason had a team-leading 789 rushing yards and scored three touchdowns. Being placed on IR means he's not eligible to play until the regular-season finale at Arizona. McCaffrey had 53 yards on seven carries on Sunday night and caught two passes for 14 yards before exiting. He was playing in just his fourth game of the season after missing the first eight because of Achilles tendinitis. McCaffrey was the NFL Offensive Player of the Year last season, when he led the league with 2,023 yards from scrimmage: a league-leading 1,459 rushing yards and 14 touchdowns plus 67 catches for 564 yards and seven scores. McCaffrey hasn't scored a touchdown in his four appearances this season. He has rushed for 202 yards on 50 carries and caught 15 passes for 146 yards. "It was frustrating," Shanahan said after the game. "He had a great week of practice and I could feel his urgency and stuff and thought he came out great, looking really good, and it looked like he just got his shoestring there. ... I hurt for him, and tough for our team not having him." The 49ers (5-7) played without defensive end Nick Bosa (oblique) and left tackle Trent Williams (ankle) in the 35-10 loss. San Francisco has lost three in a row heading into next Sunday's game against the Chicago Bears (4-8) in Santa Clara, Calif. San Francisco resides two games behind the NFC West-leading Seattle Seahawks (7-5) with five games remaining on the schedule. Seattle and San Francisco split their season series. --Field Level MediaNigeria’s oil and gas industry witnessed a flurry of business deals such as partnerships, acquisitions, and divestments in 2024. In the upstream sector, the year saw international oil giants like Shell and TotalEnergies relinquish their assets to local players like Seplat Energy and Oando PLC. We also saw ambitious acquisitions and partnership deals involving IOCs and indigenous oil companies. Related Stories TotalEnergies extends Deepsea Mira contract in West Africa for 3 months NNPCL slashes petrol price to N899 in Lagos, N970 in other states – PETROAN While divestments and exits were witnessed mostly in onshore operations, more investments by IOCs were observed in the offshore segment. Experts suggest that the IOCs do not want to deal with local issues such as pipeline vandalism and environmental pollution, while local companies have been hailed for their investment in this area despite the risks. The year also featured significant financial investment decisions and partnerships that would shape the future of Nigeria’s energy industry. Here are some of the major deals in Nigeria’s oil and gas industry in 2024. The Norwegian energy firm, Equinor ASA finalised the sale of its Nigerian assets, a 53.85% ownership in oil and gas lease OML 128, including a 20.21% stake in the Agbami field, to Chappal Energies for up to $1.2 billion. The sale signifies the exit of Equinor Nigeria Energy Company (ENEC) from Nigeria as the parent company said it planned to “deepen further in countries where Equinor can add the most value and build a more focused and robust international portfolio.” The deal, executed through Project Odinmim a special-purpose vehicle owned by Chappal Energies—was finalized this month, after several months of delay by Nigerian regulators. Seplat Energy Plc, listed on both the Nigerian Exchange Limited and the London Stock Exchange, also completed the acquisition of Mobil Producing Nigeria Unlimited MPNU from ExxonMobil Corporation. The acquisition of the onshore asset is expected to double Seplat’s production capacity to approximately 120,000 barrels of oil equivalent per day. The deal valued at $1.2 billion was initiated in February 2022 but delayed by regulatory review until December 2024. In a deal expected to be finalised in the next couple of weeks, TotalEnergies has decided to divest from Nigeria’s onshore operations in favour of a more secure offshore environment by selling its 10% stake in the Shell Petroleum Development Company to an Indigenous company, Chappal Energies. SPDC JV is an onshore subsidiary of oil giant, Shell which has been sold to a consortium of local companies. TotalEnergies Nigeria planned to transfer its 10% interest and all associated rights and obligations in 15 SPDC JV licenses to Chappal Energies. In 2023, production from these licenses accounted for roughly 14,000 barrels of oil equivalent per day for TotalEnergies. Additionally, TotalEnergies EP Nigeria will sell its 10% interest in three other SPDC JV licenses (OML 23, OML 28, and OML 77), which focus on gas production, to Chappal Energies. However, TotalEnergies will retain full economic rights in these gas-producing licenses, which currently provide 40% of the gas supply to Nigeria LNG. This year, Oando Plc completed the acquisition of the Nigerian Agip Oil Company (NAOC) from Italian energy giant Eni in a deal worth $783 million. The acquisition was part of another divestment in the oil and gas industry as Eni quits onshore operations in Nigeria for offshore operations. Speaking on NAOC’s acquisition, the Group Chief Executive of Oando PLC, Wale Tinubu, said : “Today’s announcement is the culmination of ten years of hard work, resilience, and an unwavering belief that we would realise our ambition. It is a win, not just for Oando, but for every indigenous energy player as we take our destiny in our hands. “This is a new dawn for the Nigerian energy sector, and we are confident that indigenous companies will play a pivotal role in this next phase of the nation’s upstream evolution. With our assumption of the role of operator, our immediate focus is on optimizing the assets’ immense potential in contributing to our strategic objectives, whilst complementing the nation’s plan to boost production outputs.” Nairametrics recently reported the final investment decision (FID) of Shell Nigeria Exploration and Production Company Limited (SNEPCo) on the Bonga North deep-water project, located off Nigeria’s coast. The $5 billion offshore investment, in which Shell has a 55% stake, is expected to yield approximately 350 million barrels of crude oil. The Bonga North project includes the drilling and completion of 16 wells, modifications to the existing FPSO, and the installation of new subsea infrastructure. This development is expected to maintain oil and gas production at the Bonga facility. Speaking on the investment decision, Shell’s Integrated Gas and Upstream Director, Zoë Yujnovich, said: “This is another significant investment, which will help us to maintain stable liquids production from our advantaged Upstream portfolio.” Two Nigerian companies partner with Saipem to secure a contract on the Bongo North project Weeks after Shell’s FID on the Bongo North project, an Italian multinational oilfield services company in partnership with two Nigerian companies, KOA Oil & Gas and AVEON Offshore, secured a contract valued at approximately $1 billion from SNEPco to work on the oilfield. According to Saipem, the contract covers the Engineering, Procurement, Construction, and Installation (EPCI) of risers, flowlines, subsea umbilicals, and associated subsea structures. The Nigerian National Petroleum Company Limited (NNPCL) and Total Energies also announced a Final Investment Decision (FID) on the Ubeta oilfield (OML 58), in a partnership deal valued at $550 million. Nairametrics reported that this FID involves a commitment of $550 million to extract 900 billion cubic feet of non-associated natural gas from the oil field, situated approximately 85 kilometres from Port Harcourt in Nigeria’s Niger Delta Region. These partnerships, divestments, and investments shaped the oil and gas landscape in the year 2024 and it is expected that the gains and developments therefrom will impact the industry in the coming year President Bola Tinubu has pledged to boost Nigeria’s energy security by improving production and ensuring a conducive climate for private players to thrive.The NFL's security division is warning players to be aware of professional burglars targeting the homes of pro athletes. The Athletic reported Thursday that the NFL sent a memo to teams that outlines the threat. "The homes of professional athletes across multiple sports leagues have become increasingly targeted for burglaries by organized and skilled groups," read the memo, which was obtained by The Athletic. "Law enforcement officials have noted these groups appear to exploit team schedules to target athletes' homes on game days." NBC News reported Wednesday that law enforcement is working to figure out whether an international crime syndicate is involved. The Athletic reported that the memo includes tips for home security and also gives recommendations about the use of social media, such as not posting photos of items that would attract thieves. Players also learned via the memo how homes are targeted and how burglars enter. Mahomes hasn't said much about the burglary, other than to call it "disappointing" and "frustrating." "I can't get into too many of the details because the investigation is still ongoing," he said. "But obviously something that you don't want to happen to really anybody, but obviously yourself." It's not clear what was stolen from Mahomes' home in Belton, Mo., during the Oct. 6 incident. But Kelce apparently lost $20,000 in cash in the burglary at his home in Leawood, Kan., the following day when the Chiefs played the New Orleans Saints on "Monday Night Football," according to a police report. The burglary at the home of Milwaukee Bucks forward Bobby Portis in River Hills, Wis., occurred Nov. 2 during the Bucks' home game against the Cleveland Cavaliers. He said the perpetrators "took most of my prized possessions" and is offering a reward for the return of his property. "Any info that leads to the return of any of my belongings will be rewarded handsomely," Portis said. "Let me know, thank you." --Field Level Media
A look at how some of Trump's picks to lead health agencies could help carry out Kennedy's overhaulStock market today: Stocks drift higher as US markets reopen after a holiday pauseStock market today: Stocks drift higher as US markets reopen after a holiday pause
HOUSTON , Dec. 12, 2024 /PRNewswire/ -- Gravity Oilfield Services Inc. ("Gravity" or the "company"), a growth-oriented water and power infrastructure company backed by affiliates of Clearlake Capital Group, L.P. ("Clearlake"), announced today that it has agreed to sell its Gravity Water Midstream division to Delek Logistics Partners, LP (NYSE: DKL) ("Delek Logistics"). Gravity Water Midstream provides gathering, transportation, recycling, storage, and disposal solutions for produced water in the Midland Basin in Texas and the Williston Basin in North Dakota . "The acquisition of Gravity Water Midstream by Delek Logistics creates a path to continue to build incredible scale in our water midstream platform in the Midland Basin," said Rob Rice , CEO of Gravity. "I am thankful to the employees of Gravity for their focus on service and dedication to building one of the largest commercial water management platforms in the Midland and Williston Basins. Building this water midstream platform would not be possible without the incredible support and partnership of Clearlake. I am excited to welcome in this new era for water management in the Midland and Williston Basins under the capable leadership of Delek Logistics." While Gravity is divesting its water midstream assets, the company will retain ownership and operation of its power infrastructure assets, continuing its commitment to providing critical power generation offerings. Clearlake and Gravity partnered in 2017 to pursue produced water midstream opportunities. Over the last several years, Gravity has focused on organically growing its water infrastructure business to support producers in the Midland and Williston basins, and its water business segment has quickly grown into one of the largest commercial operators of disposal wells in the Midland Basin. Gravity Water Midstream developed a system comprised of 200+ miles of permanent pipeline, 46 SWD facilities, and 14 fresh water facilities with over six million barrels of storage capacity, all of which form an extensive and interconnected network. "We valued the opportunity to partner with the Gravity team as they executed a vision to build a leading water midstream platform in the Midland and Williston Basins," said José E. Feliciano, Co-Founder and Managing Partner, and Colin Leonard, Partner and Managing Director, of Clearlake. "We'd like to thank Rob and the entire Gravity Water Midstream team for their hard work and commitment to growing the business organically over the last several years." Piper Sandler & Co served as exclusive financial advisor and Vinson & Elkins LLP served as legal counsel to Gravity in connection with the transaction. About Gravity Gravity is a growth-oriented provider of energy infrastructure services to U.S. onshore oil and natural gas exploration and production companies, providing water midstream solutions, critical power generation offerings and other production focused services. Gravity has significant coverage density in the Permian Basin and benefits from a national footprint supported by facilities, operations and management personnel in several other key domestic resource plays including the Bakken, Eagle Ford, SCOOP/STACK, DJ Basin, Haynesville and Marcellus, among others. More information is available at www.gvty.com . About Clearlake Capital Group Founded in 2006, Clearlake Capital Group, L.P. is an investment firm founded operating integrated businesses across private equity, credit and other related strategies. With a sector-focused approach, the firm seeks to partner with management teams by providing patient, long-term capital to businesses that can benefit from Clearlake's operational improvement approach, O.P.S. ® The firm's core target sectors are industrials, technology, and consumer. Clearlake has over $85 billion of assets under management, and its senior investment principals have led or co-led over 400 investments. The firm is headquartered in Santa Monica, CA with affiliates in Dallas, TX, London, UK, Dublin, Ireland , Singapore , and Abu Dhabi , UAE. More information is available at www.clearlake.com and on X @Clearlake . Media Contacts: For Gravity Heather Heacock , (281) 640-3043 Marketing Communication Manager heather.heacock@gvty.com For Clearlake Jennifer Hurson , (845) 507-0571 Lambert jhurson@lambert.com View original content to download multimedia: https://www.prnewswire.com/news-releases/gravity-agrees-to-sell-water-midstream-business-to-delek-logistics-302330850.html SOURCE Gravity Oilfield Services Inc.; Clearlake Capital Group
